Palisade Bio, Inc. Common Stock (PALI) Stock
NASDAQ · PALI
1.50
Fundamentals
Market cap
$252.69M
Price / Earnings ratio
-8.6x
Price / Sales ratio
547.2x
Price / Book ratio
2.3x
Return on assets
-34.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
NeutralPALISeptember 27, 2026
MarketBeatNeutral
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
PALI

Stocktwits
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
NeutralPALIJune 29, 2026
StocktwitsNeutral
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI

PennyStocks
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
NeutralPALIMay 24, 2023
PennyStocksNeutral
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
PALI
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
161M106M53M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-16.8M
Net incomeEarnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

MarketBeat
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
NeutralPALISeptember 27, 2026
MarketBeatNeutral
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
PALI

Stocktwits
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
NeutralPALIJune 29, 2026
StocktwitsNeutral
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
PALI

PennyStocks
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
NeutralPALIMay 24, 2023
PennyStocksNeutral
Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week
PALI
About Palisade Bio, Inc. Common Stock
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
SectorHealthcare
IndustryBiotechnology
Employees14
CEOMr. J. D. Finley
IPO DateDec 20, 2006
HeadquartersDenver, CO
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. J. D. Finley | CEO, CFO & Director | 1958 |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer | 1977 |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science & Medicine | — |
| Dr. James Izanec M.D. | VP & Head of Clinical Development | — |
| Mr. Daniel J. Larkins | Head of Global Regulatory Affairs | — |
| Mr. Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing & Controls | — |
| Ms. Dawn Louro | VP & Head of Clinical Operations | — |
| Mr. Ryker Willie | Senior VP of Finance & Corporate Controller | — |
Fundamentals
Valuation
Market cap$252.69M
Price-to-sales ratio547.20
Price-to-book value2.25
Price-earnings ratio-8.60
Return on Equity-37.00%
Return on SalesN/A
Return on Assets-34.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$0.60
Income Statement
Average volume2,976,327
EBITDA$-24.09M
1 year high (52w)$2.86
1 year low (52w)$0.70
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$7.50
Est return
403.36%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.6 | +6.4 | +6.5 | +0.5 | -3.6 | +0.5 | -26.0 |



